KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Current Deferred Revenue (2016 - 2017)

Supernus Pharmaceuticals has reported Current Deferred Revenue over the past 7 years, most recently at $287000.0 for Q4 2017.

  • Quarterly Current Deferred Revenue rose 37.32% to $287000.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $287000.0 through Dec 2017, up 37.32% year-over-year, with the annual reading at $287000.0 for FY2017, 37.32% up from the prior year.
  • Current Deferred Revenue was $287000.0 for Q4 2017 at Supernus Pharmaceuticals, roughly flat from $287000.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $417000.0 in Q1 2013 and troughed at $143000.0 in Q2 2014.
  • The 5-year median for Current Deferred Revenue is $207500.0 (2016), against an average of $218350.0.
  • The largest YoY upside for Current Deferred Revenue was 79.74% in 2013 against a maximum downside of 59.84% in 2013.
  • A 5-year view of Current Deferred Revenue shows it stood at $204000.0 in 2013, then fell by 29.9% to $143000.0 in 2014, then grew by 23.08% to $176000.0 in 2015, then increased by 18.75% to $209000.0 in 2016, then soared by 37.32% to $287000.0 in 2017.
  • Per Business Quant, the three most recent readings for SUPN's Current Deferred Revenue are $287000.0 (Q4 2017), $287000.0 (Q3 2017), and $287000.0 (Q2 2017).